NCT04507971

Effects of MET-3 and MET-5 on Gut Microbiome and Metabolic Function in Men and Women With Hypertriglyceridemia

• Status: Unknown
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 20 (estimated)
• Sponsor: NuBiyota · Academic / Other
• Sex: All
• Age: 18 Years – 49 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this pilot study is to determine the effects of two human microbiome formulations (MET-3 and MET-5) on fasting serum TG concentration.

Detailed description

Obesity is a condition characterized by an excess amount of body fat, and is defined as a body mass index (BMI) of 30 kg/m² or greater. The rising prevalence of obesity in all parts of the world is of great public health concern due to the fact that obesity is associated with many causes of morbidity and mortality. Excess body fat accumulates when energy intake is greater than energy expenditure and recently, the role of the colonic microbiome has been highlighted as a potential contributor to energy balance. The obese microbiome is suggested to promote obesity due to an excess production of short-chain fatty acids, and, thus, increased colonic energy availability. The purpose of this pilot study is to determine the effects of two human microbiome formulations (MET-3 and MET-5) on fasting serum TG concentration.

Conditions

• Obesity, Metabolically Benign

Interventions

Type	Name	Description
BIOLOGICAL	MET-3	Human microbiome supplementation derived from bacterial strains isolated from fecal matter and grown in a laboratory environment

Timeline

• Start date: 2020-06-22
• Primary completion: 2021-12-31
• Completion: 2021-12-31
• First posted: 2020-08-11
• Last updated: 2020-08-11

Locations

1 site across 1 country: Canada